Morgan Stanley raised the firm’s price target on Johnson & Johnson to $171 from $169 and keeps an Equal Weight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson: Hold Rating Amid Fair Valuation and Competitive Pressures
- Drugmakers criticize Trump drug price negotiation plan, Bloomberg reports
- Pharma cos criticize Trump’s drug price negotiation plan, Bloomberg Law reports
- Johnson & Johnson submits sNDA to U.S FDA for CAPLYTA
- Nanobiotix announces regulatory harmonization, new patent for JNJ-1900